Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Change in Receivables of -$684000.0 for Q1 2026, up 26.13% on a YoY basis from -$542280.8 in Q1 2025, and down 142.46% quarter-over-quarter from $1.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Change in Receivables for 15 years, with the latest figure at -$684000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 26.13% year-over-year to -$684000.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 205.5% YoY), and the FY2025 full-year result was $236000.0, up 111.99% from the prior year.
- Change in Receivables for Q1 2026 stood at -$684000.0, down from $1.6 million in the prior quarter.
- The five-year high for Change in Receivables was $2.3 million in Q4 2022, with the low at -$10.3 million in Q3 2023.
- Historically, Change in Receivables has averaged -$1.2 million across 5 years, with a median of -$417000.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Receivables slumped 1325.03% — and 2024, when it surged 343.08%.
- Enanta Pharmaceuticals' Change in Receivables stood at $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then jumped by 343.08% to $1.1 million in 2024, then jumped by 50.28% to $1.6 million in 2025, then slumped by 142.46% to -$684000.0 in 2026.
- The last three Change in Receivables figures came in at -$684000.0 (Q1 2026), $1.6 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -684,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -684,000.00 |
| Mar 31, 2026 | -684,000.00 |
| Dec 31, 2025 | 1.61 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | -926,000.00 |
| Mar 31, 2025 | -926,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Dec 31, 2023 | -441,000.00 |
| Dec 31, 2023 | -441,000.00 |